Dr. Raghunath is the senior consultant and the director of the uro-oncology and robotic surgery department at HCG Cancer Centre, Bengaluru.
Dr. Raghunath has performed more than 3000 uro-oncological surgeries. His expertise lies in the following:
Open and robotic radical prostatectomy and pelvic lymphadenectomy for prostate cancer
Open, Laparoscopic and Robotic partial nephrectomy / Nephron sparing surgery kidney cancers (Renal cancers) and nephroureterectomy for urothelial carcinoma of kidney and Ureter.
Open and robotic radical cystectomy and ileal conduit/neobladder (to enable the patient to pass urine naturally after removal on the urinary bladder) for bladder cancers
Open and robotic adrenalectomy for benign tumours and cancers of the adrenal gland
Open and robotic retroperitoneal lymphadenectomy for testicular cancers
Open, Laparoscopic and robotic video endoscopic inguinal lymphadenectomy for penile cancers.
Treating metastatic prostate cancers with hormone therapy and immunotherapy
Treating metastatic kidney cancers with targeted therapy and immunotherapy
His areas of interest include robotic surgery and medical equipment innovations and designing.
Dr Raghunath has so far performed more than 4500 surgeries.
Training and Certifications
He completed his fellowship training in uro oncology from Rajiv Gandhi Cancer Institute & Research Centre, Delhi.
He received his training in laparoscopic and robotic urology from Taipei City Hospital and Mackey Memorial Hospital, Taipei, Taiwan.
Dr. Raghunath is the 1st uro-oncologist to establish the 1st dedicated uro-oncology department in South India at HCG.
He is the 1st uro-oncologist in south India to perform robotic radical cystectomy and total intracorporeal ileal neobladder surgery for bladder cancer and robotic perineal radical prostatectomy for prostate cancer.
Dr. Raghunath is the founder-chairman of the Global Prostate Disease Foundation, an NGO that works on creating awareness about prostate diseases among urologists and the community.
He has served as the secretary (2013) and president (2018) of the Bengaluru Urological Society. He is currently serving as the secretary for the Society of Genitourinary Oncologists (SOGO) of India.
Dr. Raghunath has served as a principal investigator for more than 20 clinical trials conducted on prostate and renal cancers.
He has authored and co-authored over 20 publications for national and international journals. He has also authored several book chapters for several uro-oncology books.
Dr. Raghunath has served as a faculty for more than 135 national and international conferences. He has also organised more than 20 conferences and live workshops.
He has been invited as an operating faculty for live demonstrations of robotic radical prostatectomy and robotic VEIL at reputed institutes like Rajiv Gandhi Cancer Institute (Delhi), Indian Cancer Congress, Bengaluru, 21st TS Jayaram Memorial Live Operative Workshop and many more. He is also a visiting professor at the Department of Uro-oncology at Minnesota University, Minneapolis.
He was one of the speakers at the TEDx DSCE event 2019 and spoke on robotic surgery.
Outcomes of Minimally Invasive Radical Prostatectomy-a Contemporary Review. Indian J Surg Oncol. 2020 Dec;11(4):580-588.
Role of RPLND and Metastasectomy in the Management of Oligometastatic Renal Cell Carcinoma. Indian J Surg Oncol. 2018 Mar;9(1):105-109.
Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma. South Asian J Cancer. 2016 Oct-Dec;5(4):167-175.
Radical Prostatectomy for Locally Advanced Prostate Cancers-Review of Literature. Indian J Surg Oncol. 2017 Jun;8(2):175-180.
Minilaparotomy radical cystoprostatectomy (Minilap RCP) in the surgical management of urinary bladder carcinoma: early experience. Jpn J Clin Oncol. 2008 Sep;38(9):611-6
HCG - The Specialist in Cancer Care, India’s largest provider of cancer care, is at the forefront of the battle against cancer. Through its network of 24 comprehensive cancer centers, spread across India, HCG has brought advanced cancer care to the doorstep of millions of people.